Evaluating High Flow Humidification Therapy in Patients With Cystic Fibrosis

NCT ID: NCT02129803

Last Updated: 2021-01-06

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-05-31

Study Completion Date

2019-05-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a single center, randomized pilot study to evaluate the clinical effectiveness of nasal high flow 20LPM humidification therapy in subjects with Cystic Fibrosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cystic Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental Therapy

High-Flow, 20 LPM (via Optiflow cannula) Heated (34C) Humidified Air

Group Type EXPERIMENTAL

High-Flow, 20 LPM (via Optiflow cannula)

Intervention Type DEVICE

Nasal high flow humidification (20LPM) therapy will be administered using Optiflow with Airvo 2.

Control Therapy (Low Flow)

Low FLow, 5 LPM (via Optiflow cannula) Room Temperature (23-26C) Ambient Air

Group Type PLACEBO_COMPARATOR

Low FLow, 5 LPM (via Optiflow cannula)

Intervention Type DEVICE

standard humidified wall medical air.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

High-Flow, 20 LPM (via Optiflow cannula)

Nasal high flow humidification (20LPM) therapy will be administered using Optiflow with Airvo 2.

Intervention Type DEVICE

Low FLow, 5 LPM (via Optiflow cannula)

standard humidified wall medical air.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed diagnosis of CF
* Hospital admission for acute pulmonary exacerbation of CF (using Fuchs criteria 4/10)
* 10 years of age and older
* Subject is able to comply with the procedures scheduled in the protocol
* Signed informed consent form

Exclusion Criteria

* Receipt of any aerosolized experimental or investigational drugs within 1 month of enrollment
* Subject had ear, nose, and throat (ENT) surgery, nasal bleeding, or nasal polyps within 6 months prior to study
* Subject is unlikely to comply with the procedures scheduled in the protocol
* Inability to give informed consent
* Subject requires supplemental oxygen
* History of obstructive sleep apnea
* History of pressure headaches requiring therapy within one month of enrollment
* Any other medical or psychological condition in which the study doctor(s) believe(s) would inhibit the individual from being an appropriate study subject.
Minimum Eligible Age

10 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Virginia Commonwealth University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bruce K Rubin, MD

Role: PRINCIPAL_INVESTIGATOR

Virginia Commonwealth University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Children's Hospital of Richmond at VCU

Richmond, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HM20002205

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

HFNT During Exercise in CF
NCT03965832 COMPLETED NA
Oxygen Therapy in Cystic Fibrosis
NCT01586728 TERMINATED NA